Prevail Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights – GlobeNewswire
Preliminary Data Demonstrates Normalization of CSF GBA1 Enzyme Activity in Parkinsons Disease with GBA1 Mutations and Neuronopathic Gaucher Disease Patients
Company Modifies Protocol for PROPEL Trial of PR001 for Parkinsons Disease Patients with GBA1 Mutations; Expects to Continue Enrollment in Second Half of 2020
PROVIDE Trial of PR001 for Type 2 Gaucher Disease and PROCLAIM Trial of PR006 for Frontotemporal Dementia Patients with GRN Mutations Expected to Initiate Enrollment in Second Half o…
